Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Vitiligo and Skin Cancer Risk: Phototherapy, Genetics, and Immune Protection
Description
The speaker reviewed evidence on vitiligo and cancer risk, focusing on whether depigmented skin and treatments like phototherapy increase skin cancer risk. Genetic studies suggest an inverse relationship between vitiligo and melanoma, with some tyrosinase variants predisposing to one while protecting against the other. Clinical studies of melanoma-associated depigmentation showed that vitiligo-like lesions during immunotherapy differ from classic vitiligo and often signal a favorable response to anti–PD-1 treatment and better survival. Multiple cohort and registry studies consistently found that people with vitiligo have a lower incidence of melanoma and non-melanoma skin cancers, likely reflecting enhanced immune surveillance; some studies also reported reduced risks of other cancers, though thyroid cancer may be increased. Regarding treatment safety, narrowband UVB phototherapy did not increase melanoma or non-melanoma skin cancer risk overall, even with high cumulative sessions, though very high exposure may raise actinic keratosis risk. Topical calcineurin inhibitors, alone or combined with phototherapy, were not linked to increased cancer risk. Overall, the talk concluded that vitiligo is not associated with higher skin cancer risk and may even be protective, while phototherapy remains necessary for repigmentation and appears broadly safe when used appropriately.
View moreConclusions
- Across multiple cohort and registry studies, vitiligo appears to be associated with a lower risk of melanoma and non-melanoma skin cancers rather than a higher one.
- The inverse genetic relationship between vitiligo susceptibility and melanoma risk suggests shared immune or pigmentation pathways that may help explain this protective association.
- Vitiligo-like depigmentation arising during anti-PD-1 immunotherapy is clinically distinct from classic vitiligo and is often a marker of better tumor response and improved survival in melanoma.
- Narrowband UVB phototherapy for vitiligo does not appear to meaningfully increase melanoma or non-melanoma skin cancer risk, even with very high cumulative exposure, although actinic keratosis may rise after heavy treatment.
- Topical calcineurin inhibitors used alone or with phototherapy were not associated with increased lymphoma or skin cancer risk in the studied vitiligo cohorts.
- The overall evidence is reassuring for patients with vitiligo, supporting the idea that the disease may reflect enhanced immune surveillance and may function as a form of natural protection against some cancers.
- Despite these reassuring safety data, repigmentation usually still requires light-based therapy, so clinicians must balance treatment needs with long-term risk monitoring.
- Estimating the burden of vitiligo: a systematic review and modelling study.
- Variant of TYR and Autoimmunity Susceptibility Loci in Generalized Vitiligo.
- Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.#10.1016/j.jaad.2016.10.044
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.#10.1001/jamadermatol.2015.2707
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis.#10.1200/jco.2014.57.4756
- Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo.#10.1016/j.jaad.2007.10.060
- Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo.#10.1016/j.jaad.2014.07.050
- Risk of Melanoma and Nonmelanoma Skin Cancer in People with Vitiligo: United Kingdom Population-Based Cohort Study.#10.1016/j.jid.2023.04.013
- Evaluation for Skin Cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy.#10.1001/jamadermatol.2020.0218
- The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.#10.3410/f.739448404.793594872
- Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.#10.1200/jco.18.01223
- Vitiligo: the white armour?